Initial assessment of tumor-associated antigen CA-125 in patients with ovarian, cervical, and testicular tumors.
Serum CA-125, a glycoprotein antigen, has been measured in serum of patients with ovarian cancer, cervical cancer, or nonseminomatous germ-cell tumor of testis. Increased concentrations were found in 21 of 27 patients with epithelial ovarian cancer and two of three patients with ovarian teratoma. Changes in CA-125 concentrations in serum during chemotherapy mirrored the progress of the disease as assessed by clinical and radiological evidence. Although CA-125 provides no real asset for diagnosis, it should have value as a marker for monitoring response to chemotherapy.
D000328:Adult; D000951:Antigens, Neoplasm / Q000032:analysis*; D000954:Antigens, Surface; D015295:Antigens, Tumor-Associated, Carbohydrate; D016190:Carboplatin; D002277:Carcinoma / Q000188:drug therapy / Q000276:immunology; D005260:Female; D006801:Humans; D008297:Male; D009373:Neoplasms, Germ Cell and Embryonal / Q000188:drug therapy / Q000276:immunology; D009944:Organoplatinum Compounds / Q000627:therapeutic use; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000276:immunology*; D013724:Teratoma / Q000188:drug therapy / Q000276:immunology; D013736:Testicular Neoplasms / Q000188:drug therapy / Q000276:immunology*; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy / Q000276:immunology*
D000951:Antigens, Neoplasm; D000954:Antigens, Surface; D015295:Antigens, Tumor-Associated, Carbohydrate; D009944:Organoplatinum Compounds; D016190:Carboplatin